Media Articles Related to Proventil ( Inhalation)
Accidental Inhalation Of Betadine During Surgery Leads To Rare Complication
Source: Cleft Palate News From Medical News Today [2013.02.25]
A routine step in preparing for cleft palate surgery in a child led to an unusual - but not unprecedented - case of lung inflammation (pneumonitis), according to a report in the The Journal of...
400,000-year-old dental tartar provides earliest evidence of manmade pollution
Source: Respiratory / Asthma News From Medical News Today [2015.06.18]
A new discovery has revealed an early prehistoric 'balanced' diet and presence of respiratory irritants that could have resulted from smoke inhalation from indoor fires used for roasting meat.
Chronic nicotine exposure could change the structure of the stomach
Source: Endocrinology News From Medical News Today [2015.06.16]
In a study published in Experimental Physiology, researchers have found that different ways of chronic nicotine administration (oral, inhalation and injection) caused changes in hormones secreted...
Published Studies Related to Proventil ( Inhalation)
Evaluation of intravenous anthrax immune globulin for treatment of inhalation
Bacillus anthracis toxins can be neutralized by antibodies against protective
antigen (PA), a component of anthrax toxins. Anthrivig (human anthrax
immunoglobulin), also known as AIGIV, derived from plasma of humans immunized
with BioThrax (anthrax vaccine adsorbed), is under development for the treatment
of toxemia following exposure to anthrax spores.
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a
phase II randomised study. 
This phase II, randomised, double-blind, multicentre study (NCT00930982)
investigated the safety and efficacy of ciprofloxacin dry powder for inhalation
(DPI) in patients with non-cystic fibrosis bronchiectasis. Adults who were
culture positive for pre-defined potential respiratory pathogens (including
Pseudomonas aeruginosa and Haemophilus influenzae) were randomised to
ciprofloxacin DPI 32.5 mg or placebo administered twice daily for 28 days (with
56 days of follow-up).
Pilot study comparing total intravenous anesthesia to inhalational anesthesia in
endoscopic sinus surgery: novel approach of blood flow quantification. 
and blood loss... CONCLUSIONS: The intraoperative blood flow, as determined by optical rhinometry,
Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. [2011.10]
CONCLUSIONS: Inhaled loxapine was generally safe and well tolerated and produced rapid improvement in agitated patients with psychotic disorders. Statistically significant differences in efficacy were found for the 10-mg dose compared with placebo, with results suggesting 5 mg may be effective. The delivery of loxapine by inhalation may provide a rapid, well-tolerated option for treating acute psychotic agitation that allows patients to avoid the aversive effects and loss of autonomy often associated with use of intramuscular medications. Further investigation of this new loxapine formulation is warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00369577. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
CO(2) Inhalation as a Treatment for Apnea of Prematurity: A Randomized Double-Blind Controlled Trial. [2011.09.08]
OBJECTIVE: To compare the effect of prolonged inhalation of a low concentration of CO(2) with theophylline for the treatment of apnea of prematurity... CONCLUSIONS: Because theophylline was more effective in reducing the number and severity of apneas, inhalation of low concentration of CO(2), as used in the present study, cannot be considered as an alternative to theophylline in the treatment of apnea of prematurity. The less effectiveness of CO(2) treatment may have been related to the variability of the delivery of CO(2). Copyright (c) 2011 Mosby, Inc. All rights reserved.
Clinical Trials Related to Proventil ( Inhalation)
Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma [Completed]
The purpose of this study is to compare the safety and tolerability of levalbuterol HFA
metered dose inhaler (MDI) versus racemic albuterol HFA MDI in pediatric subjects 4-11 years
of age with asthma
Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients [Active, not recruiting]
This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA
Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of metered
dose inhaler (MDI) of Albuterol (Treatment T), in comparison with:
1. Placebo control: (HFA propellant only, Treatment P); and
2. Active control: 3M/Key's Proventil-HFA (Treatment R).
The treatments will be given as self-administered oral inhalations in adult and adolescent
patients with mild-to-moderate asthma, for 12-weeks. Dosing regimen throughout the 12-week
study is two actuations four times daily (QID).
Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD) [Completed]
The purpose of this study is to compare the efficacy of two dose levels of levalbuterol
compared with one dose level of racemic albuterol in pediatric subjects aged birth to 48
Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma [Completed]
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects [Completed]
An analysis of the costs and outcomes associated with hospitalization and treatment of
Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.
Reports of Suspected Proventil ( Inhalation) Side Effects
Product Quality Issue (29),
Drug Dose Omission (25),
NO Adverse Event (21),
Drug Ineffective (15),
OFF Label USE (3),
NO Therapeutic Response (3), more >>